###begin article-title 0
###xml 28 54 28 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oncostatin M receptor-&#946;</italic>
Promoter DNA Methylation of Oncostatin M receptor-beta as a Novel Diagnostic and Therapeutic Marker in Colon Cancer
###end article-title 0
###begin p 1
Conceived and designed the experiments: MSK WVC DS. Performed the experiments: MSK JL BC JSTsD. Analyzed the data: MSK JL YKC. Contributed reagents/materials/analysis tools: MSK KY JL KLO SL RGP SD ZY ND GAM. Wrote the paper: MSK HLP DS.
###end p 1
###begin p 2
###xml 524 550 524 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oncostatin M receptor-&#946;</italic>
###xml 552 556 549 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 674 678 671 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 806 810 803 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1065 1069 1062 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1108 1112 1105 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1232 1236 1229 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1363 1367 1360 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 191 196 <span type="species:ncbi:9606">human</span>
###xml 637 645 <span type="species:ncbi:9606">patients</span>
###xml 865 873 <span type="species:ncbi:9606">patients</span>
In addition to genetic changes, the occurrence of epigenetic alterations is associated with accumulation of both genetic and epigenetic events that promote the development and progression of human cancer. Previously, we reported a set of candidate genes that comprise part of the emerging "cancer methylome". In the present study, we first tested 23 candidate genes for promoter methylation in a small number of primary colon tumor tissues and controls. Based on these results, we then examined the methylation frequency of Oncostatin M receptor-beta (OSMR) in a larger number of tissue and stool DNA samples collected from colon cancer patients and controls. We found that OSMR was frequently methylated in primary colon cancer tissues (80%, 80/100), but not in normal tissues (4%, 4/100). Methylation of OSMR was also detected in stool DNA from colorectal cancer patients (38%, 26/69) (cut-off in TaqMan-MSP, 4). Detection of other methylated markers in stool DNA improved sensitivity with little effect on specificity. Promoter methylation mediated silencing of OSMR in cell lines, and CRC cells with low OSMR expression were resistant to growth inhibition by Oncostatin M. Our data provide a biologic rationale for silencing of OSMR in colon cancer progression and highlight a new therapeutic target in this disease. Moreover, detection and quantification of OSMR promoter methylation in fecal DNA is a highly specific diagnostic biomarker for CRC.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 151 154 151 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Jemal1">[1]</xref>
###xml 834 837 834 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Arnold1">[2]</xref>
###xml 839 842 839 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Fearon1">[3]</xref>
###xml 844 847 844 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Kinzler1">[4]</xref>
###xml 64 67 <span type="species:ncbi:9606">men</span>
###xml 72 77 <span type="species:ncbi:9606">women</span>
Colorectal cancer (CRC) is one of the most common cancers among men and women and accounts for 10% of all new cancer cases and cancer deaths each year [1]. The overall 5-year survival rate from colon cancer has increased during the past 20 years because of early detection from increased screening. In spite of much progress, more advanced knowledge of the molecular pathogenesis of CRC or key environmental/dietary factors in CRC development is still needed. Moreover, finding potential diagnostic markers and therapeutic targets for CRC will aid in the early detection and treatment of colon cancer. Most CRCs arise from adenomatous precursors, and accumulation of gain-of-function mutations in proto-oncogenes and loss-of-function mutations in tumor suppressor genes (TSGs) leads to progression of adenomatous lesions to carcinoma [2], [3], [4].
###end p 4
###begin p 5
###xml 197 200 197 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Jones1">[5]</xref>
###xml 567 570 567 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Herman1">[6]</xref>
###xml 594 597 594 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Baylin1">[7]</xref>
###xml 599 602 599 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Jones2">[8]</xref>
###xml 727 730 727 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Paz1">[9]</xref>
###xml 732 736 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Xu1">[10]</xref>
###xml 738 742 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Lind1">[11]</xref>
###xml 250 255 <span type="species:ncbi:9606">human</span>
###xml 414 419 <span type="species:ncbi:9606">human</span>
###xml 553 558 <span type="species:ncbi:9606">human</span>
In addition to genetic alterations involving mutations of oncogenes and TSGs, carcinogenic progression from benign neoplasm to adenocarcinoma can occur through epigenetic changes in gene promoters [5]. Aberrant gene expression is a characteristic of human cancers, and changes in DNA methylation status can have profound effects on the expression of genes. TSGs display both genetic and epigenetic inactivation in human tumors, and the transcriptional silencing of TSGs has established hypermethylation as a common mechanism for loss of TSG function in human cancers [6] including colon cancer [7], [8]. Thus, knowledge of methylation patterns across the genome can help to identify key TSGs inactivated during tumor formation [9], [10], [11].
###end p 5
###begin p 6
###xml 237 241 237 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Hoque1">[12]</xref>
Previously, we reported a set of candidate genes that comprise part of the emerging "cancer methylome" by using a new promoter structure algorithm and microarray data generated from 22 cancer cell lines derived form 5 major cancer types [12]. In this earlier study, we examined newly identified cancer-specific methylated genes in a panel of 300 primary tumors representing 13 types of cancer. Based on the data, the number of known cancer-specific methylated genes was increased by approximately 40%.
###end p 6
###begin p 7
###xml 216 242 216 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Oncostatin M receptor-&#946;</italic>
###xml 244 248 241 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 254 286 251 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-1,4-galactosyltransferase-1</italic>
###xml 288 294 282 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT</italic>
###xml 579 583 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 588 594 582 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT</italic>
###xml 750 754 744 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 791 795 785 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 177 185 <span type="species:ncbi:9606">patients</span>
###xml 512 520 <span type="species:ncbi:9606">patients</span>
###xml 559 567 <span type="species:ncbi:9606">patients</span>
In the present study, we re-examined the methylation status of cancer-specific methylated genes in a larger number of tissue and stool DNA from colon cancer patients as well as patients without cancer. We found that Oncostatin M receptor-beta (OSMR) and beta-1,4-galactosyltransferase-1 (B4GALT) were highly methylated in primary CRC tissues but rarely in corresponding normal adjacent mucosa nor in non-malignant normal colon tissues. Methylation of these genes was also detected in stool DNA from colon cancer patients, but generally absent from non-cancer patients. Moreover, OSMR and B4GALT mRNA expression in colon cancer tissues was significantly down-regulated as compared to normal tissues. Functional studies revealed a suppressive role for OSMR in colon cancer progression. Hence, OSMR methylation is biologically relevant and can be frequently detected in primary CRC tumors and matched stool DNA.
###end p 7
###begin title 8
Results
###end title 8
###begin p 9
###xml 173 177 173 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Hoque1">[12]</xref>
###xml 198 207 198 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sirtuin 2</italic>
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIRT2</italic>
###xml 379 417 379 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O6-methylguanine-DNA methyltransferase</italic>
###xml 419 423 419 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 547 550 547 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Paz1">[9]</xref>
###xml 567 571 567 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 612 647 612 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Secreted frizzled related protein 4</italic>
###xml 649 654 649 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP4</italic>
###xml 713 717 713 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Uthoff1">[16]</xref>
###xml 719 723 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Qi1">[17]</xref>
###xml 798 842 798 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Neurotrophin tyrosine kinase receptor type 2</italic>
###xml 844 849 844 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK2</italic>
###xml 855 891 855 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">urokinase type plasminogen activator</italic>
###xml 893 897 893 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLAU</italic>
###xml 1165 1174 1165 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006555.s001">Figure S1</xref>
###xml 1253 1260 1253 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006555-t001">Table 1</xref>
###xml 29 34 <span type="species:ncbi:9606">human</span>
Microarray analysis in three human colon cancer cell lines (HCT116, HT-29 and DLD1) identified 52 potential gene targets based on reactivation after treatment with 5-aza-dC [12]. Of these 52 genes, sirtuin 2 (SIRT2) was counted twice in our candidate gene list because it has two different gene identification numbers (NM_012237 and NM_030593) in the NCBI database. In addition, O6-methylguanine-DNA methyltransferase (MGMT) was previously reported to harbor cancer-specific promoter methylation in multiple types of cancer including colon cancer [9], so we excluded MGMT from our further analysis (52 -2 = 50). Secreted frizzled related protein 4 (SFRP4) was previously reported to be methylated in colon cancer [16], [17] and was included as a positive control for gene methylation in our study. Neurotrophin tyrosine kinase receptor type 2 (NTRK2) and urokinase type plasminogen activator (PLAU) were also included because no reports on methylation of the two genes in colon cancer have been published yet. We thus examined the methylation status of a total of 50 genes by bisulfite-sequencing or C-MSP in colon cancer cell lines (HCT116, DLD1, RKO, and SW480) (Figure S1). As a result, we found 23 genes to be methylated in more than one cell line (Table 1). Methylation in the other 27 genes was not detected in any of the cell lines tested.
###end p 9
###begin title 10
Methylation profiles in CRC cell lines.
###end title 10
###begin p 11
When "methylation positive" was detected in any single cell line, it was considered as methylation (M) in cell lines.
###end p 11
###begin p 12
No CpG islands in GPR116 and SLC39A4 were found within 1 kb upstream of the TSS.
###end p 12
###begin p 13
C10orf119, SECTM1 and NTRK2 were only methylated in one cell line.
###end p 13
###begin p 14
M, methylated; U, unmethylated. n/d, not determined.
###end p 14
###begin p 15
###xml 474 522 474 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3&#8242;-phosphoadenosine 5&#8242;-phosphosulfate synthase 2</italic>
###xml 524 530 524 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAPSS2</italic>
###xml 533 553 533 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;-tubulin gene 2</italic>
###xml 555 560 551 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TUBG2</italic>
###xml 563 568 559 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK2</italic>
###xml 570 577 566 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 583 587 579 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 599 604 595 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP4</italic>
###xml 672 679 668 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006555-t002">Table 2</xref>
###xml 770 773 766 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 793 796 789 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 953 962 949 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g001">Figure 1A</xref>
###xml 967 976 963 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006555.s002">Figure S2</xref>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
###xml 265 267 <span type="species:ncbi:9606">NN</span>
###xml 353 361 <span type="species:ncbi:9606">patients</span>
###xml 410 412 <span type="species:ncbi:9606">NN</span>
###xml 737 739 <span type="species:ncbi:9606">NN</span>
###xml 767 769 <span type="species:ncbi:9606">NN</span>
To identify genes harboring cancer-specific promoter methylation, we examined the methylation status of the 23 genes in five to ten pairs of matched primary CRC (PT) and corresponding normal colon (PN) tissues. Normal colon mucosa tissues from non-cancer patients (NN) were also included to compare methylation specificity between cancer and non-cancer patients. We excluded genes that harbored methylation in NN with frequencies higher than 30%. As a result, we found that 3'-phosphoadenosine 5'-phosphosulfate synthase 2 (PAPSS2), gamma-tubulin gene 2 (TUBG2), NTRK2, B4GALT1, and OSMR as well as SFRP4 harbored cancer-specific methylation with high frequencies (>30%) (Table 2). All 6 of these genes did not harbor methylation in all NN tested, and differences in NN vs. PT and methylation vs. unmethylation cases were statistically significant. Representative results of C-MSP, bisulfite-sequencing, and COBRA in cell lines and tissues are shown in Figure 1A and Figure S2.
###end p 15
###begin title 16
Promoter methylation analysis.
###end title 16
###begin p 17
###xml 208 216 208 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 381 391 381 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-actin</italic>
###xml 430 437 427 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC39A4</italic>
###xml 442 450 439 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC9A3R1</italic>
###xml 503 508 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GANAB</italic>
###xml 510 514 507 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLAU</italic>
###xml 519 524 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UBE3A</italic>
###xml 793 797 790 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 860 864 857 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Hoque1">[12]</xref>
###xml 1132 1139 1129 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006555-t003">Table 3</xref>
###xml 1264 1271 1261 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 1276 1280 1273 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1344 1351 1341 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 1389 1393 1386 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1747 1768 1744 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 1808 1815 1805 1812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 1820 1824 1817 1821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1867 1874 1864 1871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 1879 1883 1876 1880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1970 1977 1967 1974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 1992 1996 1989 1993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 247 252 <span type="species:ncbi:9606">human</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
###xml 722 724 <span type="species:ncbi:9606">NN</span>
###xml 766 774 <span type="species:ncbi:9606">patients</span>
###xml 1211 1213 <span type="species:ncbi:9606">NN</span>
A, Methylation status of each gene was examined in CRC cell lines and tissues by C-MSP after PCR with methylation-specific primers. PCR products were run on 4% agarose gels pre-stained with ethidium bromide. In vitro methylated, bisulfite-treated human normal lymphocyte DNA (NL) was used as a positive control for PCR, and distilled water (DW) was used as a negative PCR control. beta-actin was used to confirm integrity of DNA. SLC39A4 and SLC9A3R1 were methylated both in cell lines and tissues, but GANAB, PLAU and UBE3A were not. The other 5 genes were methylated in one of three cells lines tested, and only methylated in CRC tissues (PT). PN, paired normal colon tissues from colon cancer patients; PT, paired CRC; NN, normal colon epithelium from non-cancer patients. C-MSP results of OSMR in CRC cell lines and tissues were shown in a previous report [12]. B, Scatter plots of methylation values of six candidate genes in tissues and cell lines (CL). The overall methylation values (TaqMan methylation values, TaqMeth V) and the optimal specificity/sensitivity at optimal cut-offs calculated from ROC analysis are shown in Table 3. Arrows indicate the optimal cut-off values for each gene. No cases of NN displayed TaqMeth V over the optimal cut-offs for B4GALT1 and OSMR. HEK293, a non-tumorigenic cell line, harbored a high level of B4GALT1 methylation (TaqMeth V, 101.12), but OSMR methylation was not detected in the cell line (TaqMeth V, 0.00). *, Samples with a ratio equal to zero could not be plotted correctly on a log scale, so are presented here as 0.1. All assays were performed in duplicate format, and experiments were repeated twice. Data showed reproducible and concordant results in triplicate. TaqMeth V is described in Materials and Methods. C, Quantitative methylation levels of B4GALT1 and OSMR in primary colon tissues. Scatter plot of B4GALT1 and OSMR promoter methylation. Arrows indicate optimal cut-off values for each gene (3.877 for B4GALT1 and 22.01 for OSMR).
###end p 17
###begin title 18
Methylation profiles in colon tissues.
###end title 18
###begin p 19
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 74 76 <span type="species:ncbi:9606">NN</span>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
PN, corresponding normal colon mucosa from CRC patients; PT, CRC tissues; NN, colon normal epithelium from non-cancer patients.
###end p 19
###begin p 20
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 32 52 32 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fisher's exact test.</italic>
P value was calculated from the Fisher's exact test.
###end p 20
###begin p 21
PT vs. PN.
###end p 21
###begin p 22
###xml 7 9 <span type="species:ncbi:9606">NN</span>
PT vs. NN.
###end p 22
###begin p 23
P<0.05 was considered significant.
###end p 23
###begin p 24
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p&lt;0.05</italic>
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 91 93 <span type="species:ncbi:9606">NN</span>
Determination of genes harboring cancer-specific methylation was based on p<0.05 in PT vs. NN.
###end p 24
###begin p 25
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n/a</italic>
n/a, not assessed.
###end p 25
###begin p 26
###xml 165 174 165 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006555.s003">Figure S3</xref>
###xml 425 434 425 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g001">Figure 1B</xref>
###xml 657 664 657 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006555-t003">Table 3</xref>
###xml 666 673 666 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 678 682 678 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 831 838 831 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.001</italic>
###xml 863 870 863 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.001</italic>
###xml 1000 1012 1000 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAPSS2 TUBG2</italic>
###xml 1014 1019 1014 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK2</italic>
###xml 1025 1030 1025 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP4</italic>
###xml 1191 1198 1191 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 1273 1277 1273 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
###xml 355 357 <span type="species:ncbi:9606">NN</span>
###xml 756 758 <span type="species:ncbi:9606">NN</span>
###xml 859 861 <span type="species:ncbi:9606">NN</span>
To study promoter methylation of these 6 genes by TaqMan-MSP real-time analysis, we designed primers and probes specifically targeting the CpG islands of each gene (Figure S3). We increased the sample numbers to over 25 pairs of primary CRC (PT) and corresponding normal colon (PN) tissues, and to 13 normal colon mucosa tissues from non-cancer patients (NN). The distribution of methylation values for each gene is shown in Figure 1B. Due to heterogenous clonal patches known to expand beyond the tumor borders, a low level of methylation in PN was also commonly observed. The overall methylation values (TaqMan methylation values, TaqMeth V) are shown in Table 3. B4GALT1 and OSMR harbored higher levels of overall methylation in PT than those in PN and NN, and the differences were significant for both genes between PT and PN (P<0.001) and between PT and NN (P<0.001). When methylation values were compared within individual pairs of PN and PT samples, significantly higher methylation levels of PAPSS2 TUBG2, NTRK2, and SFRP4 were found in 60% (18/30), 50% (15/30), 30% (9/30), and 36% (11/30), respectively, in PN than in corresponding tumor samples (PT). Higher methylation levels of B4GALT1 in PN samples was found only in 4 cases (13.3%, 4/30), and methylation of OSMR was not found in any of the paired normals (0%, 0/25).
###end p 26
###begin title 27
Sensitivity and specificity of gene methylation at optimal cut-off values for detection of colon cancer tissue.
###end title 27
###begin p 28
###xml 67 88 65 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
TaqMeth V is expressed as mean+/-SD, and TaqMeth V is described in Materials and Methods.
###end p 28
###begin p 29
P value was derived from Wilcoxon matched-pairs signed-ranks test.
###end p 29
###begin p 30
###xml 3 6 3 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
PT vs. PN.
###end p 30
###begin p 31
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
P<0.01 was considered significant.
###end p 31
###begin p 32
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 29 50 29 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wilcoxon-Mann-Whitney</italic>
P value was derived from the Wilcoxon-Mann-Whitney test.
###end p 32
###begin p 33
###xml 3 6 3 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 7 9 <span type="species:ncbi:9606">NN</span>
PT vs. NN.
###end p 33
###begin p 34
AUROC is expressed as mean+/-SD, and optimal cut-off values were calculated from ROC analysis.
###end p 34
###begin p 35
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 28 31 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 32 34 <span type="species:ncbi:9606">NN</span>
P value in ROC analysis (PT vs. NN).
###end p 35
###begin p 36
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 11 25 11 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fisher's exact</italic>
###xml 35 38 35 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 39 41 <span type="species:ncbi:9606">NN</span>
P value in Fisher's exact test (PT vs. NN).
###end p 36
###begin p 37
###xml 112 114 <span type="species:ncbi:9606">NN</span>
Sensitivity, positive methylation/total tumor cases (PT); Specificity, negative methylation/total normal cases (NN).
###end p 37
###begin p 38
###xml 50 53 50 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 54 56 <span type="species:ncbi:9606">NN</span>
% Methylation in PN was based on cut-offs from PT vs. NN.
###end p 38
###begin p 39
Methylation level below the cut-offs was considered as unmethylated and over the cut-offs were as methylated.
###end p 39
###begin p 40
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 74 76 <span type="species:ncbi:9606">NN</span>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
PN, corresponding normal colon mucosa from CRC patients; PT, CRC tissues; NN, colon normal epithelium from non-cancer patients.
###end p 40
###begin p 41
###xml 184 191 184 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.001</italic>
###xml 194 204 194 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006555.s004">Figure S4A</xref>
###xml 394 396 394 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
###xml 419 426 419 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006555-t003">Table 3</xref>
###xml 598 605 598 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 610 614 610 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 656 663 656 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 668 672 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 749 756 749 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 761 765 761 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 854 861 854 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 866 870 866 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 179 181 <span type="species:ncbi:9606">NN</span>
###xml 398 400 <span type="species:ncbi:9606">NN</span>
###xml 545 547 <span type="species:ncbi:9606">NN</span>
Methylation of the 6 genes in tissue showed highly discriminative receiver-operator characteristic (ROC) curve profiles, clearly distinguishing CRC (PT) from normal colon mucosa (NN) (P<0.001) (Figure S4A). AUROC (Area under ROC) was over 0.76 in all genes tested. In order to maximize sensitivity and specificity, the optimal cut-offs for the 6 genes were calculated from the ROC analysis (PT vs. NN) and are shown in Table 3. At cut-offs set for optimal specificity of 90% or more, the sensitivity of each gene in PT was over 70%. No cases of NN displayed TaqMeth V over the optimal cut-offs for B4GALT1 and OSMR (100% specificity). The sensitivities of B4GALT1 and OSMR were 83% (25/30) and 80% (20/25), respectively. These results indicate that B4GALT1 and OSMR harbor cancer-specific methylation in CRC with high frequency. Therefore, we focused on B4GALT1 and OSMR for further study.
###end p 41
###begin p 42
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 146 153 146 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g001">Fig. 1C</xref>
###xml 224 231 224 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 346 353 346 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 392 396 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 432 439 432 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 444 448 444 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 483 490 481 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 515 519 511 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 606 613 598 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 635 639 625 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 662 669 650 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.001</italic>
###xml 714 721 702 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 736 740 724 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 779 781 767 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
###xml 788 798 776 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006555.s004">Figure S4B</xref>
###xml 869 876 857 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 881 885 869 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 952 959 940 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 964 968 952 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
We examined the methylation status of B4GALT1 and OSMR in 100 new pairs of CRC (PT) and corresponding normal (PN) tissues by TaqMan-MSP analysis (Fig. 1C). The TaqMeth V in PT ranged from 0 to 370.70 (median value 3.70) for B4GALT1 and from 0 to 749.27 (median value 59.24) for OSMR. The value in PN ranged from 0 to 9.70 (median value 0.26) for B4GALT1 and to 190.68 (median value 1.54) for OSMR. The overall methylation levels of B4GALT1 and OSMR detected in PT (22.33+/-48.69 for B4GALT1 and 116.83+/-151.52 for OSMR, mean+/-SD, n = 100) were also significantly higher than those in PN (0.90+/-1.37 for B4GALT1 and 6.49+/-21.52 for OSMR, mean+/-SD, n = 100) (P<0.001). At the optimal cut-offs (values, 3.87 for B4GALT1 and 22.01 for OSMR) calculated from the ROC analysis (PT vs. PN) (Figure S4B), the specificity of the two genes was over 96%. The sensitivities of B4GALT1 and OSMR were 49% (49/100) and 80% (80/100), respectively. Taken together, B4GALT1 and OSMR were frequently methylated in primary CRC tissues but displayed absent or low levels of methylation in corresponding normal tissues.
###end p 42
###begin p 43
###xml 258 263 258 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Suzuki1">[18]</xref>
###xml 397 405 397 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g002">Figure 2</xref>
###xml 407 414 407 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006555-t004">Table 4</xref>
###xml 510 515 510 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 726 733 726 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 738 742 738 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 860 865 860 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 870 874 870 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1026 1031 1026 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 1035 1039 1035 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1083 1089 1083 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.01</italic>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
###xml 548 556 <span type="species:ncbi:9606">patients</span>
###xml 638 646 <span type="species:ncbi:9606">patients</span>
###xml 816 824 <span type="species:ncbi:9606">patients</span>
###xml 982 990 <span type="species:ncbi:9606">patients</span>
###xml 1014 1022 <span type="species:ncbi:9606">patients</span>
Next, we performed a blinded analysis of gene methylation analysis in stool DNA collected from patients with or without colon cancer. The clinical status of the patients was not revealed until the analysis was completed. We also examined hypermethylation of SFRP1 as a positive control for detection of gene methylation in stool DNA [18]. The results of ROC analysis in the stool DNA are shown in Figure 2. Table 4 shows the sensitivity/specificity of each gene for colon cancer detected in stool DNA samples. SFRP1 methylation was not detected in patients with endoscopically normal colon (0%, 0/15), and was found in 55% (11/20) of CRC patients, at the optimal cut-off value calculated from the ROC analysis. Methylation of B4GALT1 and OSMR was detected in 64% (9/14) and 80% (16/20) of stool DNA samples from CRC patients, respectively. When methylation of SFRP1 and OSMR was combined, the sensitivity was 60% (12/20), and the specificity was 100% (0/15). Discrimination between patients without cancer and CRC patients by SFRP1 or OSMR methylation was statistically significant (P<0.01).
###end p 43
###begin title 44
ROC curve analysis in stool DNA.
###end title 44
###begin p 45
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 313 320 313 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006555-t004">Table 4</xref>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
A blinded test was performed for gene methylation analysis in stool DNA collected from patients with or without colon cancer. SFRP1 was included to compare methylation frequency of a known cancer-specific methylated gene. Sensitivity/specificity based on optimal cut-offs calculated from ROC analysis is shown in Table 4.
###end p 45
###begin title 46
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Gene methylation detected in stool from colon cancer or non-cancer patients.
###end title 46
###begin p 47
Methylation positivity and negativity based on methylation level at cut-off values; 0 for SFRP1, 0 for B4GALT1 and 8.53 for OSMR. M(+), Methylation positive.
###end p 47
###begin p 48
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with endoscopically normal colon (diverticulosis, diarrhea, polyps or bloody stool).
###end p 48
###begin p 49
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with colorectal cancer.
###end p 49
###begin p 50
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with adenoma.
###end p 50
###begin p 51
Sum of methylation from SFRP1 and OSMR. Sum of methylation positivity was calculated by counting cases determined to be methylation-positive for at least one gene.
###end p 51
###begin p 52
Sum of methylation negativity was calculated by counting cases determined to be methylation-negative for each gene.
###end p 52
###begin p 53
###xml 0 14 0 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fisher's exact</italic>
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sup>
###xml 45 48 45 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 57 58 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</sup>
###xml 62 65 62 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
Fisher's exact test was performed in enormal vs.CRC, and fCRC vs. AD; *P<0.05 was considered significant. n/a, not assesed.
###end p 53
###begin p 54
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 126 133 126 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006555-t004">Table 4</xref>
###xml 271 275 271 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 357 364 357 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006555-t005">Table 5</xref>
###xml 461 468 461 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.001</italic>
###xml 484 488 484 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 731 735 731 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 885 889 885 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
###xml 394 402 <span type="species:ncbi:9606">patients</span>
###xml 588 596 <span type="species:ncbi:9606">patients</span>
###xml 681 689 <span type="species:ncbi:9606">patients</span>
OSMR methylation was tested in a blinded fashion in one more independent set of stool samples (no overlap with the samples in Table 4). Stool DNA from healthy control subjects who had no visual abnormalties in colonoscopy were included for this study. The sensitivity of OSMR methylation in CRC patients was 38% (26/69) and the specificity was 95% (77/81) (Table 5). The difference between CRC patients and normal controls was statistically highly significant (P<0.001). In addition, OSMR methylation was detected in 56% (15/27) and 44% (8/18) stool DNA samples from CRC stage II and III patients, respectively. Moreover, 34 of 41 cases (83%) of fecal DNA from confounding control patients without CRC were completely negative for OSMR methylation. Other clinical parameters in confounding controls such as diverticulosis, hemorrhoid, and polyps were not significantly associated with OSMR methylation status in stool (data not shown).
###end p 54
###begin title 55
OSMR methylation detected in stool samples.
###end title 55
###begin p 56
Methylation positivity and negativity based on methylation level of OSMR at a cut-off value 4.
###end p 56
###begin p 57
M (+), Methylation positive.
###end p 57
###begin p 58
Healthy control subjects with no visual abnormalities in colonoscopy.
###end p 58
###begin p 59
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with colorectal cancer.
###end p 59
###begin p 60
I-IV, UICC stages.
###end p 60
###begin p 61
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients without CRC (polyps, diverticulosis, and hemorrhoid)
###end p 61
###begin p 62
###xml 14 28 14 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fisher's exact</italic>
###xml 56 59 56 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
P values from Fisher's exact test performed in Controls vs.CRC. *P<0.05, significant.
###end p 62
###begin p 63
###xml 13 27 13 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fisher's exact</italic>
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
P value from Fisher's exact test between total CRC vs.Confounding controls.
###end p 63
###begin p 64
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 109 115 109 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g003">Fig. 3</xref>
###xml 236 240 236 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 356 360 356 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 418 422 418 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Hoque1">[12]</xref>
###xml 454 458 454 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 525 532 525 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 629 636 629 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 647 654 647 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 690 700 690 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006555.s005">Figure S5A</xref>
To examine the transcriptional levels of B4GALT1 and OSMR, we performed RT-PCR or Real-time RT-PCR analysis (Fig. 3) using cDNA prepared from CRC cell lines (HCT116, HT29, DLD-1, RKO, and SW480) and a non-tumorigenic cell line, HEK293. OSMR expression was observed only in the cells where methylation of OSMR was not found (HCT116 and HEK293). Increase of OSMR expression by 5-aza-dC treatment was previously reported [12], indicating that expression of OSMR correlates tightly with promoter methylation. Basal expression of B4GALT1 was detected in all cell lines tested, and all of these cell lines also harbored methylation of B4GALT1. However, B4GALT1 was further increased by 5-Aza-dC (Figure S5A), indicating that its expression was at least partially suppressed by promoter methylation.
###end p 64
###begin title 65
Expression of B4GALT1 and OSMR.
###end title 65
###begin p 66
###xml 17 24 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 96 103 96 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 360 364 357 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</italic>
###xml 381 388 378 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 397 401 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 488 493 485 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</italic>
###xml 584 591 581 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 596 600 593 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 708 714 703 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
###xml 787 793 780 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
###xml 355 357 <span type="species:ncbi:9606">PT</span>
###xml 433 441 <span type="species:ncbi:9606">patients</span>
###xml 483 485 <span type="species:ncbi:9606">NN</span>
A, Expression of B4GALT1 and OSMR in cell lines was examined by RT-PCR analysis. Methylation of B4GALT1 in the cell lines was examined by C-MSP or TaqMan-MSP. beta-actin was used as a loading control. M, methylation; U, unmethylation. B and C, Real-time RT-PCR was performed in five pairs (a - e) of normal (PN) and tumor cDNA prepared from CRC patients (PT) (left). Expression of B4GALT1 (B) and OSMR (C) were also compared between patients with colon cancer (T) or without cancer (NN) (right). Relative expression (Fold) was calculated by comparing the ratios of mRNA expression of B4GALT1 and OSMR to an internal control gene, GAPDH. Experiments were done in duplicate, and values indicate means+/-SD. *, P<0.05. Experiments were done in duplicate, and values indicate means+/-SD. *, P<0.05.
###end p 66
###begin p 67
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 225 232 225 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g003">Fig. 3C</xref>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</italic>
###xml 259 266 259 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 271 275 271 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 358 371 358 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g003">Fig. 3B and C</xref>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</italic>
###xml 521 525 521 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 633 639 633 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g004">Fig. 4</xref>
###xml 644 651 644 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006555-t006">Table 6</xref>
###xml 663 667 663 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 806 810 806 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 64 66 <span type="species:ncbi:9606">PT</span>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
###xml 339 341 <span type="species:ncbi:9606">NN</span>
###xml 563 565 <span type="species:ncbi:9606">NN</span>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
###xml 721 723 <span type="species:ncbi:9606">PT</span>
We then performed Real-time RT-PCR in cDNA prepared from tumor (PT) and corresponding normal tissues (PN) of five individual colon cancer patients (matched cDNA). In 3 of 5 tumor cases, OSMR was significantly down-regulated (Fig. 3C, left). The expression of B4GALT1 and OSMR in tumor was three and four times lower than in normal tissue (NN), respectively (Fig. 3B and C, right). By immunohistochemical staining of a colon normal and cancer tissue microarray with an anti-OSMR antibody, we detected strong expression of OSMR in all non-malignant normal tissues (NN) and adjacent normal colon mucosa (PN) from colon cancer patients (Fig. 4 and Table 6). However, OSMR was barely detected in almost of all primary tumors (PT) (weak expression in 4 of 10 cases). These results suggest a specific decrease of OSMR mRNA and protein in colon cancer development.
###end p 67
###begin title 68
Immunohistochemical analysis of OSMR in colon cancer tissue microarray with normal colon tissue controls.
###end title 68
###begin p 69
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 76 78 <span type="species:ncbi:9606">NN</span>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
Strong expression of OSMR was detected in all non-malignant normal tissues (NN) and adjacent normal colon mucosa (PN). In contrast, OSMR was rarely detected in the neoplastic cells from colon cancer patients. Tumor grades are indicated.
###end p 69
###begin title 70
Immunohistochemical analysis of OSMR in colon cancer tissue microarray with normal tissue controls.
###end title 70
###begin p 71
Note, expression level is indicated as -, no or very faint expression.
###end p 71
###begin p 72
+ mild expression
###end p 72
###begin p 73
++ moderate expression.
###end p 73
###begin p 74
+++ strong expression.
###end p 74
###begin p 75
++++ very strong expression.
###end p 75
###begin p 76
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 155 159 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 195 199 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 282 285 282 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sss</italic>
###xml 334 338 334 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 454 461 454 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g005">Fig. 5A</xref>
###xml 498 501 498 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sss</italic>
To investigate the role of DNA methylation in regulation of OSMR expression, we transfected a pGL3-OSMR-Pro2-Luciferase construct into three cell lines; a OSMR-negative cell line, SW480, and two OSMR-positive cell lines, HCT116 and HEK293. The construct was treated with or without SssI methylase before transfection. Activity of the OSMR promoter was not detected in SW480, but a high level of promoter activity was detected in HCT116 and HEK293 cells (Fig. 5A). Induction of CpG methylation with SssI methylase decreased the activity to minimal levels.
###end p 76
###begin title 77
Cellular function of OSMR.
###end title 77
###begin p 78
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 189 192 189 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sss</italic>
###xml 471 475 469 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 590 594 588 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</italic>
###xml 750 755 747 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</italic>
###xml 912 921 907 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*, P&lt;0.05</italic>
###xml 1137 1143 1131 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
###xml 1217 1223 1211 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
###xml 1252 1257 1246 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat3</italic>
###xml 1262 1265 1256 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Erk</italic>
###xml 1394 1399 1388 1393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat3</italic>
###xml 1404 1407 1398 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Erk</italic>
###xml 1523 1528 1517 1522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat3</italic>
###xml 1530 1533 1524 1527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Erk</italic>
###xml 1538 1548 1532 1539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-actin</italic>
###xml 1593 1597 1584 1588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1679 1688 1670 1679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006555.s006">Figure S6</xref>
###xml 1708 1712 1699 1703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIFR</italic>
###xml 1717 1722 1708 1713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gp130</italic>
###xml 1765 1769 1756 1760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIFR</italic>
###xml 1850 1855 1841 1846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gp130</italic>
###xml 1861 1865 1852 1856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
A, Analysis of OSMR promoter activity by luciferase reporter assay in OSMR-positive (HCT116 and HEK293) and - negative (SW480) cells. The promoter construct was pre-treated with or without SssI methylase for 8 hrs before transfection. The highest activity was detected in HEK293 cells. Data are expressed as fold increase over pGL3-basic activity. Experiments were done in triplicate, and values indicate means+/-SD. Mean values are presented. B, An siRNA pool targeting OSMR and non-targeting control were transiently transfected into HCT116, and cells were treated with rhOSM (50 ng/ml) (left). HCT116 cells were treated with or without Stat3 inhibitor peptide (Stat3 Inh, 100 muM) acting as a highly selective, potent blocker of Stat3 activation (right). Cell growth was determined by MTT assay. Data are expressed as absorbance at 570 nm. Experiments were done in triplicate, and values indicate means+/-SD. *, P<0.05. C, 5-Aza-dC (5 muM) was pre-treated for 48 hrs in SW480 and DLD-1 cells, and then co-treated with rhOSM for 48 hrs. Cell growth was determined by MTT assay. *, 5-Aza-dC-treated cells compared to untreated control (P<0.05); #, 5-Aza-dC/rhOSM- treated cells compared to 5-Aza-dC treatment alone (P<0.05). D, The phosphorylation of Stat3 and Erk in response to rhOSM (50 ng/ml) was analyzed by Western blotting in HCT116 and SW480 cell lines. rhOSM increased phosphorylated Stat3 and Erk in HCT116 cells but not in SW480 cells (which lack LIFR-see E below). Equal protein loading was monitored by total Stat3, Erk and beta-actin evaluation in the samples. Re-activation of OSMR by 5-Aza-dC treatment was determined on SW480 and DLD-1 cells by flow cytometry (Figure S6). E. Expression of LIFR and gp130 was examined in CRC cell lines by RT-PCR. LIFR was expressed in HCT116 cells but silenced in most other CRC cell lines tested. gp130, the OSMR heterodimer, was ubiquitously expressed in all cell lines tested. Promoter methylation status of these two latter genes was not examined.
###end p 78
###begin p 79
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Zarling1">[19]</xref>
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Grant1">[20]</xref>
###xml 258 262 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 296 300 296 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Lacreusette1">[15]</xref>
###xml 465 469 465 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 718 722 718 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 724 731 724 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g005">Fig. 5B</xref>
###xml 811 818 811 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g005">Fig. 5D</xref>
###xml 881 888 881 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g005">Fig. 5B</xref>
###xml 995 999 995 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1022 1029 1022 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g005">Fig. 5C</xref>
###xml 1128 1134 1128 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
###xml 1193 1199 1193 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.05</italic>
###xml 1317 1324 1317 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g005">Fig. 5D</xref>
###xml 1347 1352 1347 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gp130</italic>
###xml 1357 1361 1357 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIFR</italic>
###xml 1397 1404 1397 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g005">Fig. 5E</xref>
###xml 1669 1673 1669 1673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1730 1734 1730 1734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 1780 1787 1780 1787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006555-g005">Fig. 5D</xref>
###xml 1941 1945 1941 1945 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 582 587 <span type="species:ncbi:9606">human</span>
Oncostatin M (OSM) is an interleukin-6 (IL-6)-type cytokine, but more active than IL-6 in inhibiting the proliferation of numerous solid tumor cell lines [19], [20]. Recently, a correlation of resistance to growth inhibition by OSM with specific loss of the OSMR and Stat3 signaling was reported [15]. In order to examine CRC cell resistance to growth inhibition by OSM, we transiently transfected a siRNA pool targeting OSMR and a non-targeting control siRNA into OSMR-expressing HCT116 cells, and performed a standard cell growth assay after treatment of cells with a recombinant human OSM (rhOSM). We observed significant growth inhibition by rhOSM in HCT116 cells, and the inhibition was reversed by knock-down of OSMR (Fig. 5B, left). A Stat3 inhibitor peptide (Stat3 Inh) that abrogated Stat3 activation (Fig. 5D) blocked the rhOSM-induced growth inhibition in HCT116 cells (Fig. 5B, right). Consistently, suppression of cell growth by rhOSM was not observed in SW480 and DLD-1 cells with OSMR promoter methylation (Fig. 5C). Interestingly, the inhibition of cell growth by 5-Aza-dC treatment in SW480 and DLD-1 cells (*, P<0.05) was significantly enhanced by the treatment of rhOSM (#, P<0.05). Finally we observed that rhOSM activated Stat3 phosphorylation in HCT116 cells, regardless OSMR expression levels (Fig. 5D, left). Expression of gp130 and LIFR mRNA was observed in HCT116 cells (Fig. 5E), indicating that the activation of Stat3 in HCT116 cells with very low OSMR expression caused by siRNA transfection may be through gp130/LIFR (type I OSM receptor)-mediated signaling. Erk phosphorylation increased in HCT116 cells transfected with siRNA targeting OSMR, and the basal level of phospho-Erk in SW480 cells with OSMR methylation was higher than in HCT116 cells (Fig. 5D). 5-Aza-dC partially decreased activated Erk in SW480 cells, and rhOSM recovered basal Erk phopshorylation in the presence of 5-Aza-dC. Thus, methylated OSMR markedly decreased tumor-inhibiting signals from rhOSM and key downstream signaling events.
###end p 79
###begin title 80
Discussion
###end title 80
###begin p 81
Promoter methylation of key regulatory genes drives the cancer process and in the right context can serve as a diagnostic marker and a therapeutic target. Cancer-specific methylation serves as an important biomarker for the early detection of cancer. Such markers may supplement the cytopathological assessment of tissue biopsies or potentially stand on their own as markers of disease in various bodily fluids such as stool. To this end, the methylation frequency of genes identified in primary tissues has important clinical implications.
###end p 81
###begin p 82
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hMLH1</italic>
###xml 91 99 91 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p16INK4a</italic>
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14ARF</italic>
###xml 109 117 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAR-&#946;</italic>
###xml 119 122 116 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APC</italic>
###xml 124 128 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 130 139 127 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cyclin A1</italic>
###xml 141 145 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDX1</italic>
###xml 147 152 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOD1</italic>
###xml 154 159 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COX-2</italic>
###xml 164 168 161 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT-1</italic>
###xml 168 172 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Esteller1">[21]</xref>
###xml 174 178 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Xu2">[22]</xref>
###xml 180 184 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Lind2">[23]</xref>
###xml 309 315 306 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAPSS2</italic>
###xml 317 322 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TUBG2</italic>
###xml 324 329 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTRK2</italic>
###xml 331 338 328 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 343 347 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 347 351 344 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Hoque1">[12]</xref>
###xml 353 357 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Deng1">[24]</xref>
###xml 668 720 665 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyclin A1, CDX1, RAR-&#946;, MYOD1, p15INK4b and COX-2</italic>
###xml 750 754 744 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Xu1">[10]</xref>
###xml 417 422 <span type="species:ncbi:9606">human</span>
A number of genes are commonly hypermethylated in colorectal cancer (CRC) including hMLH1, p16INK4a, p14ARF, RAR-beta, APC, MGMT, cyclin A1, CDX1, MYOD1, COX-2 and WT-1[21], [22], [23]. However, genes methylated only in neoplastic tissues with high frequency (over 40%) are rare. In this study, we identified PAPSS2, TUBG2, NTRK2, B4GALT1 and OSMR[12], [24] as genes harboring cancer-specific promoter methylation in human colorectal cancer. The theoretical sensitivity of each methylated gene was over 70% and the specificities were over 90% by TaqMan-MSP. The methylation frequency of each gene ranks with only a few other genes methylated at high frequency in CRC (Cyclin A1, CDX1, RAR-beta, MYOD1, p15INK4b and COX-2) in a cancer-specific manner [10].
###end p 82
###begin p 83
###xml 11 18 11 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 64 71 64 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 135 139 135 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Zhu1">[25]</xref>
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Seko1">[26]</xref>
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Alahari1">[27]</xref>
###xml 290 297 290 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 381 385 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Inoue1">[28]</xref>
###xml 501 505 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Zhu2">[29]</xref>
###xml 507 514 507 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 593 597 593 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Li1">[30]</xref>
###xml 675 679 675 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Zhang1">[31]</xref>
###xml 743 750 743 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 750 754 750 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Zhu1">[25]</xref>
###xml 903 910 903 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 926 930 926 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Asano1">[32]</xref>
###xml 948 955 948 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 198 203 <span type="species:ncbi:9606">human</span>
###xml 301 306 <span type="species:ncbi:9606">human</span>
###xml 647 652 <span type="species:ncbi:9606">human</span>
###xml 921 925 <span type="species:ncbi:10090">mice</span>
Studies on B4GALT1 and OSMR have been reported in human cancer. B4GALT1 is localized both in the Golgi complex and on the cell surface [25], and is constitutively expressed in all tissues including human colorectal mucosa [26] with the exception of the brain [27]. The role of cell surface B4GALT1 in human cancer has been reported; it is an estrogen-regulated gene in MCF-7 cells [28], and its level was altered in highly metastatic lung cancer cells compared with its less metastatic parental cells [29]. B4GALT1 promotes apoptosis by inhibiting the epidermal growth factor receptor pathway [30] and increases cycloheximide-induced apoptosis in human hepatocarcinoma cells [31]. Protein kinase B/Akt inhibits apoptosis by down-regulation of B4GALT1[25]. In addition, enhanced epithelial cell proliferation of the skin and small intestine and abnormal differentiation in intestinal villi were found in B4GALT1-deficient mice [32], suggesting that B4GALT1 plays an important and suppressive role in the proliferation of epithelial cells. Thus, its inactivation by promoter methylation could lead to escape of normal cellular controls and cancer progression.
###end p 83
###begin p 84
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Malik1">[33]</xref>
###xml 230 234 230 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Brown1">[34]</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Ganapathi1">[35]</xref>
###xml 323 327 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Ohata1">[36]</xref>
###xml 347 351 347 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Douglas1">[37]</xref>
###xml 670 674 670 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Lacreusette1">[15]</xref>
###xml 130 135 <span type="species:ncbi:9606">Human</span>
###xml 998 1003 <span type="species:ncbi:9606">human</span>
OSMR is a receptor of Oncostatin M (OSM), an interleukin-6 (IL-6)-type cytokine identified as a potent suppressor of tumor cells. Human OSM was originally described by its capacity to inhibit melanoma proliferation in vitro [33], [34], and its targets for growth inhibition include lung carcinomas [35], ovarian carcinomas [36], and breast tumors [37]. Resistance to growth inhibition by OSM in metastatic melanoma cell lines correlated with a specific loss of OSMR, in conjunction with a lower level of histone acetylation in the OSMR promoter region, suggesting that metastatic melanoma cells could escape the growth control of OSM by the epigenetic silencing of OSMR [15]. We discovered that promoter methylation strongly correlates with OSMR expression and also found a correlation of resistance to growth inhibition by OSM with loss of OSMR in CRC cell lines. Thus, promoter methylation is a key regulator of OSMR expression and all of these results support a suppressive function for OSMR in human cancer.
###end p 84
###begin p 85
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Gearing1">[39]</xref>
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Mosley1">[40]</xref>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-UnderhillDay1">[41]</xref>
###xml 607 611 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Amado1">[42]</xref>
###xml 978 982 978 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-UnderhillDay1">[41]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human OSM forms two types of heterodimeric signaling complexes; gp130/leukemia inhibitory factor receptor (LIFR) (type I OSM receptor complex) [39] and gp130/OSMR (type II OSM receptor complex) [40]. gp130/LIFR can be activated by LIF or OSM, but gp130/OSMR is activated by OSM only. The type II receptor complex activates OSM-specific signaling pathways via the JNK/SAPK and Stat1/Stat5 pathways, whereas both type I and type II complexes activate Stat3 and Erk as common signaling pathways in breast cancer cells [41]. In addition, type I and type II receptor signaling may exhibit antagonistic functions [42]. We found that OSM-mediated cell growth inhibition was not observed in HCT116 cells with low OSMR level despite Stat 3 phosphorylation. Since HCT116 cells expressed gp130 and LIFR, rhOSM likely phosphorylates Stat3 through type I OSM receptor-mediated signaling, but in the absence of gp130/OSMR this effect is not sufficient to mediate sustained growth suppression [41]. In support of this notion, rhOSM did not increase Stat3 phosphorylation in SW480 cells which lack LIFR expression
###end p 85
###begin p 86
###xml 199 206 199 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 398 403 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP1</italic>
###xml 403 407 403 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Suzuki1">[18]</xref>
###xml 429 433 429 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 556 563 556 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;0.001</italic>
###xml 614 618 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
From a clinical point of view, our results have potential immediate diagnostic and therapeutic implications and deserve further attention. In a blinded test performed in stool DNA from CRC patients, B4GALT1 and OSMR methylation were successfully detected with high frequency and thus have potential for identifying individuals with colon cancer. When we tested an additional known methylated gene, SFRP1[18], in combination with OSMR the sensitivity of the assay increased; 60% (12/20) of colon cancers were detected in stool DNA with perfect specificity (P<0.001). These data suggest that promoter methylation of OSMR might serve as a true indicator for the presence of colon cancer.
###end p 86
###begin p 87
###xml 104 111 104 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Li1">[30]</xref>
###xml 419 423 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Amado1">[42]</xref>
###xml 425 429 425 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Livre1">[43]</xref>
###xml 482 487 482 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K-ras</italic>
###xml 514 521 514 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 586 590 586 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
Therapeutically, both genes provide tantalizing clues for new approaches in the treatment of CRC. Since B4GALT1 promotes apoptosis by inhibiting the epidermal growth factor receptor pathway [30], strategies to reverse promoter methylation and re-express the gene might augment treatment with antibodies against the EGFR receptor. Kras mutation is known to be a strong indicator of resistance to EGFR targeted therapies [42], [43]. It would be interesting to know how many wild type K-ras colorectal cancers harbor B4GALT1 methylation as a mechanism of EGFR resistance. Demethylation of OSMR could also have therapeutic impact by re-sensitizing cells to the inhibitory effects of OSM. This approach could have an impact on multiple tumors types beyond CRC since so many tumors have been found to be inhibited by OSM. Finally, one could even envision a combined approach where the addition of demethylation agents and OSM to anti-EGFR antibodies could target colon cancer cells and greatly diminish their chance of therapeutic escape.
###end p 87
###begin title 88
Materials and Methods
###end title 88
###begin title 89
Cell lines and tissues
###end title 89
###begin p 90
###xml 406 410 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Kim1">[13]</xref>
###xml 170 176 <span type="species:ncbi:9913">bovine</span>
###xml 330 332 <span type="species:ncbi:9606">PT</span>
###xml 438 440 <span type="species:ncbi:9606">PT</span>
###xml 521 523 <span type="species:ncbi:9606">NN</span>
###xml 544 552 <span type="species:ncbi:9606">patients</span>
###xml 661 669 <span type="species:ncbi:9606">patients</span>
###xml 671 679 <span type="species:ncbi:9606">patients</span>
###xml 843 851 <span type="species:ncbi:9606">patients</span>
Five CRC cell lines (HCT116, DLD1, RKO, SW480 and HT29) were purchased from ATCC (Manassas, VA). CRC cell lines were grown in 5X McCoy medium supplemented with 10% fetal bovine serum. HEK293 cells were obtained from ATCC and were grown in DMEM supplemented with 10% FBS. One hundred pairs of gDNA from primary colorectal cancers (PT) and matched normal adjacent colon mucosa (PN) were described previously [13]. For statistical purposes, PT and PN were treated as paired groups. Thirteen normal colon epithelial tissues (NN) were obtained from patients without cancer from the Department of Pathology, The Johns Hopkins University. Stool gDNA from colon cancer patients, patients without cancer, and healthy control subjects were kindly provided by OncoMethylome Sciences (Sart-Tilman, Belgium). Written informed consent was obtained from the patients who provided the colon epithelial tissues and the stool gDNA, and this study was approved by the Institutional Review Board of the Johns Hopkins University in US and Vrije Universiteit Medisch Centrum in Belgium.
###end p 90
###begin title 91
DNA purification from stool DNA and bisulfite treatment
###end title 91
###begin p 92
###xml 189 194 <span type="species:ncbi:9606">human</span>
Stool specimens were collected and immediately submerged in stool stabilization buffer (Exact Sciences, MA) and stored at room temperature until processing (within 72 hrs). For recovery of human DNA, whole samples were homogenized in excess volume (1:7) of stool homogenization buffer (Exact Sciences, MA) and aliquoted in portions of 32 ml (the equivalent of 4 g of stool). Each aliquot of stool samples were centrifuged and the supernatants were incubated with RNase A for 1 hr at 37degreesC. The DNA was then precipitated with sodium acetate (pH 5.2) - isopropanol and washed with 70% ethanol. The DNA pellet was subsequently re-suspended in 4 ml of 1x TE (pH 7.4) and proteinase K digested by the use of 400 microl of 10X buffer (240 mM EDTA, 750 mM NaCl, pH 8.0), 400 microl of 10% SDS and 20 microl of proteinase K (20 mg/ml), and samples were incubated overnight at 48degreesC with constant shaking. After centrifugation, 5 ml of phenol/chloroform/isoamylalcohol was added and samples were incubated (with shaking at 225 rpm) for 10 min at RT. After centrifugation again, the aqueous layer was transferred into new tubes, and DNA was precipitated and washed. Pellets were re-suspended in 2 ml of 1x TE solution (pH 8.0). Bisulfite treatment of 1 microg of tissue gDNA was performed to convert unmethylated cytosines to uracils for methylation analysis. For stool DNA, an up-scaled DNA modification step was applied to 32 microg of the obtained DNA, using the EZ-96DNA Methylation Kit (Zymo Research, Los Angeles, CA), according to the manufacturer's protocol. Bisulfite-treated DNA was concentrated using the Clean and Concentrator Kit (Zymo Research) and eluted in 30 microl.
###end p 92
###begin title 93
Sequencing and Combined Bisulfite Restriction Analysis (COBRA)
###end title 93
###begin p 94
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Kim2">[14]</xref>
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Hoque1">[12]</xref>
###xml 645 650 645 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BstU1</italic>
All PCR reactions were done as described previously [14], and the primer sequences of bisulfite-DNA amplification were described previously [12]. PCR products were gel-extracted (Qiagen, Valencia, CA) and sequenced with an internal primer (F2) or forward primer (F1) using the ABI BigDye cycle sequencing kit (Applied Biosystems, Foster City, CA). Searches for CpG islands in each gene promoter were done by using the online accessible software Methprimer. Bisulfite-sequencing primers were designed at the CpG islands within 1 or 2 kb upstream of the transcription start site (TSS). For COBRA, eluted DNA after gel extraction was digested with BstU1 (New England Biolabs., Beverly, MA), which recognizes the CGCG sequence, for 3 hrs at 60degreesC. Samples were loaded on a 10% acrylamide gel, stained with 1X SYBR Green Gold (Molecular Probes, Eugene, Oregon), and visualized under UV light.
###end p 94
###begin title 95
The criteria to determine methylation in cell lines and tissues
###end title 95
###begin p 96
Bisulfite-sequencing was based on nucleotide sequences in electropherograms. When only a cytosine or a thymidine peak existed in a CpG, the sequence was "CG" (100% methylation) or "TG" (0% methylation). When both methylated and unmethylated alleles were observed in a CpG sequence, it was considered as "partially methylated" (M/U). When "partial methylated CpG" was observed, a cytosine peak was compared to a thymidine peak in the CpG. If a cytosine peak was similar to a thymidine peak or dominant, the sequence in electropherograms was "NG" or "CG", indicating that over 50% methylated alleles existed. When a thymidine peak was dominant, the sequence was "TG", indicating less than 50% methylated alleles. Only "NG" and "CG" were considered as "methylated" in the CpG. When "methylated" CpG was found in more than 50% of total CpGs in an amplified PCR product, it was considered as "methylation-positive." When any CRC cell line was "methylation-positive," it was classified as "methylation". Methylation in tissues was determined when "methylation-positive" cases were observed in over 30% of total tissues tested (over 30% frequency).
###end p 96
###begin title 97
Conventional methylation-specific PCR (C-MSP)
###end title 97
###begin p 98
###xml 148 156 148 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006555.s007">Table S1</xref>
Bisulfite-treated DNA was amplified with either methylation-specific or unmethylation-specific primers for each gene. Primer sequences are shown in Table S1. PCR reactions were performed for 35 cycles of 95degreesC for 30 sec, 58degreesC for 30 sec, and 72degreesC for 30 sec. When clear PCR products amplified with methylation-specific primers were detected, it was considered as "methylation-positive." Determination of overall methylation in cell lines and tissues were the same as described above.
###end p 98
###begin title 99
Quantitative methylation-specific PCR (TaqMan-MSP)
###end title 99
###begin p 100
###xml 325 333 325 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006555.s008">Table S2</xref>
###xml 521 525 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Kim2">[14]</xref>
###xml 787 795 787 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1052 1060 1052 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1073 1077 1073 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SssI</italic>
###xml 1722 1751 1714 1743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TUBG2, NTRK2, SFRP4, and OSMR</italic>
###xml 1762 1769 1754 1761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B4GALT1</italic>
###xml 1774 1780 1766 1772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAPSS2</italic>
###xml 715 722 <span type="species:ncbi:9606">patient</span>
For quantitative methylation analysis, PCR primers were designed to hybridize to the region of each gene that was determined to be methylated in CRC cell lines by bisulfite-sequencing or C-MSP, and a fluorescent probe was synthesized to the amplified region of the DNA. Primer and probe sequences for TaqMan-MSP are shown in Table S2. All oligonucleotide primer pairs were purchased from Invitrogen (Carlsbad, CA), and the TaqMan probe from VWR (West Chester, PA). All protocols for TaqMan-MSP were performed as reported [14], and all reactions were performed in duplicate. To ensure the specificity of the TaqMan-MSP analysis, each 384-well PCR plate had wells that contained bisulfite-converted DNA isolated from patient tissue samples and wells that contained the following controls: in vitro methylated normal lymphocyte DNA (NL, positive control), DNA from normal colon mucosa in which each gene is not methylated (negative control), and multiple water blanks (control for PCR specificity). Lymphocyte DNA from a healthy individual was methylated in vitro with excess SssI methyltransferase (New England Biolabs Inc., Beverly, MA) to generate completely methylated DNA, and serial dilutions (90-0.009 ng) of the DNA were used to construct a calibration curve for each plate. All samples were within the assay's range of sensitivity and reproducibility was based on amplification of an internal reference standard (threshold cycle [CT] value for beta-actin of</=40). The methylation ratio (TaqMan methylation value, TaqMeth V) was defined as the quantity of fluorescence intensity derived from promoter amplification of each gene divided by fluorescence intensity from beta-actin amplification, and multiplied by 100 (TUBG2, NTRK2, SFRP4, and OSMR) or 1000 (B4GALT1 and PAPSS2). This ratio was used as a measure for the relative level of methylated DNA in samples. The samples were categorized as unmethylated or methylated based on optimal cut-offs from ROC analysis.
###end p 100
###begin title 101
Statistical Analysis
###end title 101
###begin p 102
We used gene methylation levels (TaqMeth V) to construct receiver operating characteristic (ROC) curves for the detection of colon cancer. In the ROC analysis, tangent points where the slopes of ROC curves were 1.00 have been selected as optimal cut-off points to balance sensitivity and specificity. P value was derived from Z value that was calculated from the equation of (AUROC-0.5)/Std Err (standard error of AUROC). The cut-off values determined from ROC curves were then applied to determine the frequency of gene methylation. Samples with a methylation level higher than cut-offs were designated as methylated, and samples with a methylation level lower than cut-offs were designated as unmethylated. All Statistical analyses in this study were conducted using STATA Version 9 (STATA Inc., College Station, TX).
###end p 102
###begin title 103
5-Aza-dC treatment, RT-PCR and Real-time RT-PCR
###end title 103
###begin p 104
###xml 1217 1218 1173 1174 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1224 1239 1180 1187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#916;(&#916;Ct)</sup>
###xml 1253 1254 1197 1198 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1258 1264 1202 1208 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t,GENE</sub>
###xml 1266 1273 1210 1217 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t,GAPDH</sub>
###xml 1291 1292 1227 1228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1302 1305 1234 1237 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t,N</sub>
###xml 1312 1315 1240 1243 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t,T</sub>
###xml 1454 1462 1382 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006555.s009">Table S3</xref>
###xml 572 577 <span type="species:ncbi:9606">human</span>
###xml 599 601 <span type="species:ncbi:9606">NN</span>
###xml 1370 1372 <span type="species:ncbi:9606">NN</span>
###xml 1398 1406 <span type="species:ncbi:9606">patients</span>
Cells were treated with 5 muM 5-aza-2'-deoxycytidine (5-Aza-dC) (Sigma, St. Louis, MO) every 24 hrs for 3 days. RNA was extracted using Trizol (Invitrogen, Carlsbad, CA) and reverse-transcribed with Superscript II reverse transcriptase (Invitrogen). RT-PCR was performed by 30 cycles of 95degreesC for 1 min, 58degreesC for 1 min, and 72degreesC for 1 min. PCR products were gel-extracted and sequenced to verify true expression of the genes. Five matched normal and tumor cDNA (a-e) were purchased from Clontech Laboratories, Inc. (Mountain View, CA), and cDNA panels of human normal colon tissue (NN) and colon cancer tissue (T) were purchased from BioChain Institute, Inc. (Hayward, CA). One mul of each cDNA was used for real-time RT-PCR using QuantiFast SYBR Green PCR Kit (Promega, Valencia, CA). Amplifications were carried out in 384-well plates in a 7900 Sequence Detector System (Perkin-Elmer Applied Biosystems, Norwalk, CT). Thermal cycling was initiated with a first denaturation step at 95degreesC for 3 minutes, followed by 40 cycles of 95degreesC for 15 seconds, 58degreesC for 30 seconds, 72degreesC for 30 seconds. Expression of genes relative to GAPDH was calculated based on the threshold cycle (Ct) as 2-Delta(DeltaCt), where DeltaCt = Ct,GENE-Ct,GAPDH and Delta (DeltaCt) = DeltaCt,N-DeltaCt,T (N, matched normal tissue cDNA; T, tumor tissue cDNA; NN, normal tissue cDNA from patients without cancer). Primer sequences are shown in Table S3.
###end p 104
###begin title 105
Immunohistochemistry
###end title 105
###begin p 106
###xml 279 283 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 284 290 <span type="species:ncbi:9986">rabbit</span>
Tissue microarrays were performed with sections (5 microm) of colon cancer tissues, adjacent tissues 1.5 cm away from tumor, and non-malignant normal colon tissues which were purchased from US Biomax, Inc. (Rockville, MD). The tissues were deparaffinized and incubated with anti-OSMR rabbit polyclonal antibody (1:100 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA) at 4degreesC overnight. They were then incubated in broad spectrum secondary antibody purchased from DAKO (Carpinteria, CA) for 30 min. After washing the slides in PBS, tissue sections were stained with freshly prepared DAB chromogen solution (DAKO). We treated tissues with streptavidin and biotin (Invitrogen) for 20 min each to block endogenous biotin levels. Sections were counterstained in Mayer's Hematoxyline.
###end p 106
###begin title 107
Luciferase reporter assay
###end title 107
###begin p 108
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Lacreusette1">[15]</xref>
###xml 244 245 244 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 305 309 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 400 407 400 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 712 719 712 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 788 792 788 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 861 869 861 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 876 879 876 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sss</italic>
The pGL3-OSMR-Pro2-Luciferase construct designed to contain a CpG island (-693 to+229 relative to the TSS) was kindly provided by Dr.  (Universite de Nantes, France) [15], and transfected into HEK293, HCT116 and SW480 cells at a density of 1x105/well in a 24-well plate. For each well, 100 ng of the pGL3-OSMR-Pro2-Luciferase constructs was co-transfected with 10 ng of internal control reporter pSV-Renilla (Promega) using Fugene-6 (Roche, Basel, Switzerland) in accordance with the manufacturer's instructions. After 48 hrs, the luciferase assay was performed using a Dual luciferase assay kit (Promega) and a single-sample luminometer (PerkinElmer, Waltham, MA). The luciferase activity was normalized by pSV-Renilla activity, and the pGL3-basic vector was used as a control. The pGL3-OSMR-Pro2-Luciferase construct and the pGL3-basic vector were methylated in vitro using SssI (CpG) methylase as recommended by the manufacturer's instructions (New England Biolabs, Beverly, MA). After DNA isolation, equal amounts (100 ng) of the methylated or unmethylated luciferase constructs were transfected into cells. Each experiment was performed twice, each in triplicate.
###end p 108
###begin title 109
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
Knockdown of OSMR and cell growth assay
###end title 109
###begin p 110
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 334 335 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
A siRNA pool targeting OSMR and non-targeting control were purchased from Dharmacon (Chicago, IL). Fifty nM of each siRNA were transiently transfected to HCT116 using LipofectamineRNAiMax transfection reagent (Invitrogen) in OPTI-MEM. After 24 hrs, cells were incubated in complete growth medium. Initial cell seeding density was 5x103/well in 24 well plates, and the antiproliferative activity of rhOSM (50 ng/ml) (R & D systems, Minneapolis, MN) was measured by the MTT assay. After 4 hr incubation in serum-deprived condition, cells were treated with rhOSM in 0.1% serum medium, and incubated for 2, 3, or 4 days as indicated. Stat3 inhibitor peptide (100 muM, cell permeable) purchased from Calbiochem (La Jolla, CA) was pre-treated for 1 hr and 30 min during serum starvation, and co-treated with rhOSM for 72 hrs. 5-Aza-dC (5 muM) (Sigma, St. Louis, MO) was pre-treated for 48 hrs, and co-treated with rhOSM.
###end p 110
###begin title 111
Western blot analyses
###end title 111
###begin p 112
###xml 277 281 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 296 299 296 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Erk</italic>
###xml 323 328 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat3</italic>
###xml 344 347 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Erk</italic>
###xml 354 359 354 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat3</italic>
###xml 368 379 368 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-&#946;-actin</italic>
###xml 740 744 731 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 762 765 753 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Erk</italic>
###xml 810 821 801 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-&#946;-actin</italic>
After pre-treatment with 5-Aza-dC or Stat3 inhibitor, rhOSM was treated in serum-free condition for 30 min, and whole cell lysates were extracted in RIPA buffer, separated on 4-12% gradient SDS-PAGE, and transferred to nitrocellulose. The blots were incubated with either anti-OSMR, anti-phospho-Erk (Tyr204), anti-phospho-Stat3 (Tyr705), anti-Erk, anti-Stat3, or anti-beta-actin antibody for 2 hrs at room temperature or 4 degreesC overnight. After antibody washing, the blots were incubated with their respective secondary antibody and detected with enhanced chemiluminescence reagents (Amersham, Pittsburgh, PA) according to the supplier's protocol. All antibodies were purchased from Cell Signaling Technology (Danvers, MA) except anti-OSMR and anti-phospho-Erk (Tyr204) (Santa Cruz Biotechnology) and anti-beta-actin (Sigma) antibodies.
###end p 112
###begin title 113
Flow cytometry analysis
###end title 113
###begin p 114
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OSMR</italic>
###xml 155 160 <span type="species:ncbi:10090">Mouse</span>
Cell surface expression of OSMR on SW480 and DLD-1 cells was detected using an anti-OSMR-phycoethryin (PE) conjugated antibody (Santa Cruz Biotechnology). Mouse IgG-PE antibody was used as an isotype control (Santa Cruz Biotechnology). Cell-associated fluorescence was acquired by a FACScaliber fluorocytometer (BD Biosciences) and analyzed using Cell-Quest software.
###end p 114
###begin title 115
Supporting Information
###end title 115
###begin p 116
Fifty-two candidate genes thought to be relevant to colon cancer by the new promoter structure algorithm were identified after initial analysis. A total of 50 genes were analyzed for detection of promoter methylation in CRC cell lines. UnM, unmethylated gene group; M, methylated gene group.
###end p 116
###begin p 117
(0.11 MB PPT)
###end p 117
###begin p 118
Click here for additional data file.
###end p 118
###begin p 119
###xml 1580 1601 1580 1601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 766 768 <span type="species:ncbi:9606">PT</span>
###xml 938 940 <span type="species:ncbi:9606">NN</span>
###xml 1034 1036 <span type="species:ncbi:9606">PT</span>
###xml 1116 1118 <span type="species:ncbi:9606">PT</span>
###xml 1222 1224 <span type="species:ncbi:9606">PT</span>
###xml 1238 1240 <span type="species:ncbi:9606">NN</span>
###xml 1282 1290 <span type="species:ncbi:9606">patients</span>
###xml 1480 1482 <span type="species:ncbi:9606">PT</span>
Representative results of bisulfite sequencing in CRC cell lines and tissues (A). Genomic and bisulfite-treated genomic DNA sequences are indicated. *, Cytosine that was not protected by methylation was thus converted to Thymidine after bisulfite treatment. Underlined CGs, methylated CpGs that were maintained after bisulfite treatment. Primer sequences for bisulfite-sequencing were described previously (12). B, Promoter methylation of TUBG2 in cell lines was examined by C-MSP (a), and in tissues was examined by COBRA after digestion of gel-extracted PCR products with BstU1 (b). Samples were loaded on a 10% acrylamide gel, stained with 1 X SYBR Green Gold (Invitrogen) and visualized under UV light. Multiple cleaved bands by BstU1 digestion were detected in PT samples (1-5) after gel separation, indicating the continued presence of protected CGCG sequences as a result of methylation, whereas no BstUI cleavage was found in any NN samples (6-10). Due to tissue heterogeneity, methylated and unmethylated alleles co-exist in PT samples so that uncleaved bands can be seen. Mock digestion (without BstU1) of PT samples resulted in the same uncleaved band as BstU1 digestion of the normal colon mucosa PCR product. PT, paired CRC; NN, normal colon epithelium from non-cancer patients. (c), Representative bisulfite-sequencing results of the TUBG2 promoter. Only methylated alleles were detected in all cell lines tested whereas methylated/unmethylated alleles coexisted in PT and PN tissues. The criteria to determine methylation in cell lines and tissues are described in Materials and Methods.
###end p 119
###begin p 120
(1.48 MB PPT)
###end p 120
###begin p 121
Click here for additional data file.
###end p 121
###begin p 122
CpG islands 1 Kb upstream of the transcription start site (TSS) in the candidate gene promoters. Graphics depicting CpG islands (gray) were taken from Methprimer software. NTRK2 and OSMR had two CpG islands and the other four genes had one CpG island within 1 Kb upstream of the TSS. Promoter regions analyzed in this study partially or completely covered the CpG islands indicated. Methylation for PAPSS2, TUBG2 and OSMR was examined at two different promoter regions. The location of the TSS is shown in each gene promoter. Primer sites for bisulfite-DNA amplification and C-MSP and TaqMan-MSP are indicated as Bi-F and Bi-R, and mF and mR, respectively. Probes for TaqMan-MSP analysis are indicated as P. Primers for C-MSP (mF-mR) were used for TapMan-MSP analysis. F, forward; R, reverse.
###end p 122
###begin p 123
(0.43 MB PPT)
###end p 123
###begin p 124
Click here for additional data file.
###end p 124
###begin p 125
###xml 44 46 <span type="species:ncbi:9606">PT</span>
###xml 51 53 <span type="species:ncbi:9606">NN</span>
###xml 122 124 <span type="species:ncbi:9606">NN</span>
###xml 130 132 <span type="species:ncbi:9606">PT</span>
###xml 257 259 <span type="species:ncbi:9606">PT</span>
###xml 324 326 <span type="species:ncbi:9606">PT</span>
A, ROC curve analysis of 6 candidate genes (PT vs. NN). Area under the ROC (AUROC) conveys the accuracy in distinguishing NN from PT in terms of sensitivity and specificity. Solid line, genes analyzed; dashed line, no discrimination. B, ROC curve analysis (PT vs. PN) of B4GALT1 (left) and OSMR (right) in 100 pairs of CRC (PT) and corresponding normal (PN) tissues.
###end p 125
###begin p 126
(0.38 MB PPT)
###end p 126
###begin p 127
Click here for additional data file.
###end p 127
###begin p 128
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006555-Hoque1">[12]</xref>
Expression of B4GALT1 and OSMR. A, B4GALT1 was reactivated by the 5-Aza-dC treatment (Aza), and OSMR reactivation by 5-Aza-dC was previously reported [12]. Fold induction was calculated by comparing the ratios of B4GALT1 or OSMR mRNA to GAPDH (an internal control) before and after treatment. Fold induction ranged from 1.7 to 4.4 for B4GALT1 and from 5.2 (HCT116) to 2,868 (DLD-1) for OSMR (12). Expression of the B4GALT1 (B) and the OSMR (C) in CRC cell lines was quantitatively compared by real-time RT-PCR. The lowest expression of OSMR was detected in SW480 cell line. Experiments were done in duplicate, and values indicate means+/-SD. *, P<0.05.
###end p 128
###begin p 129
(0.88 MB PPT)
###end p 129
###begin p 130
Click here for additional data file.
###end p 130
###begin p 131
###xml 273 278 <span type="species:ncbi:10090">Mouse</span>
Re-activation of OSMR by 5-Aza-dC treatment. Cell surface expression of OSMR was determined on SW480 and DLD-1 cells by flow cytometry. Values shown as insets correspond to the mean of fluorescent intensity ratios between cells with or without 5-Aza-dC treatment (3 days). Mouse IgG-PE antibody was used as an isotype control (data not shown).
###end p 131
###begin p 132
(0.14 MB PPT)
###end p 132
###begin p 133
Click here for additional data file.
###end p 133
###begin p 134
mF, methylation-specific forward; mR, methylation-specific reverse; uF, unmethylation-specific forward; uR, unmethylation-specific reverse. aPrimers used for detection of methylatoin in cell lines; bPimers in cell lines and tissues.
###end p 134
###begin p 135
(0.19 MB PPT)
###end p 135
###begin p 136
Click here for additional data file.
###end p 136
###begin p 137
(0.17 MB PPT)
###end p 137
###begin p 138
Click here for additional data file.
###end p 138
###begin p 139
Primers for RT-PCR are the same as for Real-Time RT-PCR.
###end p 139
###begin p 140
(0.11 MB PPT)
###end p 140
###begin p 141
Click here for additional data file.
###end p 141
###begin title 142
References
###end title 142
###begin article-title 143
Cancer statistics, 2005.
###end article-title 143
###begin article-title 144
Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis.
###end article-title 144
###begin article-title 145
A genetic model for colorectal tumorigenesis.
###end article-title 145
###begin article-title 146
Lessons from hereditary colorectal cancer.
###end article-title 146
###begin article-title 147
The fundamental role of epigenetic events in cancer.
###end article-title 147
###begin article-title 148
Hypermethylation of tumor suppressor genes in cancer.
###end article-title 148
###begin article-title 149
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
###end article-title 149
###begin article-title 150
The epigenomics of cancer.
###end article-title 150
###begin article-title 151
###xml 43 48 <span type="species:ncbi:9606">human</span>
A systematic profile of DNA methylation in human cancer cell lines.
###end article-title 151
###begin article-title 152
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
###end article-title 152
###begin article-title 153
A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines.
###end article-title 153
###begin article-title 154
Genome-wide promoter analysis uncovers portions of the cancer methylome.
###end article-title 154
###begin article-title 155
###xml 70 75 <span type="species:ncbi:9606">human</span>
The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth.
###end article-title 155
###begin article-title 156
###xml 111 116 <span type="species:ncbi:9606">human</span>
N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer.
###end article-title 156
###begin article-title 157
Loss of oncostatin M receptor beta in metastatic melanoma cells.
###end article-title 157
###begin article-title 158
###xml 75 80 <span type="species:ncbi:9606">human</span>
Wingless-type frizzled protein receptor signaling and its putative role in human colon cancer.
###end article-title 158
###begin article-title 159
Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor.
###end article-title 159
###begin article-title 160
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer.
###end article-title 160
###begin article-title 161
Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells.
###end article-title 161
###begin article-title 162
The oncostatin M signalling pathway: reversing the neoplastic phenotype?
###end article-title 162
###begin article-title 163
###xml 39 44 <span type="species:ncbi:9606">human</span>
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis.
###end article-title 163
###begin article-title 164
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
###end article-title 164
###begin article-title 165
A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines.
###end article-title 165
###begin article-title 166
Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs.
###end article-title 166
###begin article-title 167
Constitutively active PKB/Akt inhibited apoptosis and down-regulated beta1,4-galactosyltransferase 1 in hepatocarcinoma cells.
###end article-title 167
###begin article-title 168
###xml 113 118 <span type="species:ncbi:9606">human</span>
Identification and characterization of N-acetylglucosamine-6-O-sulfate-specific beta1,4-galactosyltransferase in human colorectal mucosa.
###end article-title 168
###begin article-title 169
A membrane proximal region of the integrin 5 subunit is important for its interaction with nischarin.
###end article-title 169
###begin article-title 170
Development of cDNA microarray for expression profiling of estrogen-responsive genes.
###end article-title 170
###begin article-title 171
###xml 62 67 <span type="species:ncbi:9606">human</span>
Elevated beta1,4-galactosyltransferase I in highly metastatic human lung cancer cells. Identification of E1AF as important transcription activator.
###end article-title 171
###begin article-title 172
Cell surface beta 1, 4-galactosyltransferase 1 promotes apoptosis by inhibiting epidermal growth factor receptor pathway.
###end article-title 172
###begin article-title 173
###xml 82 87 <span type="species:ncbi:9606">human</span>
Involvement of beta 1,4 galactosyltransferase 1 and Gal beta1-->4GlcNAc groups in human hepatocarcinoma cell apoptosis.
###end article-title 173
###begin article-title 174
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Growth retardation and early death of beta-1,4-galactosyltransferase knockout mice with augmented proliferation and abnormal differentiation of epithelial cells.
###end article-title 174
###begin article-title 175
Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M.
###end article-title 175
###begin article-title 176
###xml 82 87 <span type="species:ncbi:9606">human</span>
###xml 219 224 <span type="species:ncbi:9606">human</span>
Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells.
###end article-title 176
###begin article-title 177
###xml 31 36 <span type="species:ncbi:9606">human</span>
Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
###end article-title 177
###begin article-title 178
Menstrual cycle-specific inhibition of endometrial stromal cell proliferation by oncostatin M.
###end article-title 178
###begin article-title 179
Expression and function of members of the cytokine receptor superfamily on breast cancer cells.
###end article-title 179
###begin article-title 180
Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.
###end article-title 180
###begin article-title 181
The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor.
###end article-title 181
###begin article-title 182
Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation.
###end article-title 182
###begin article-title 183
Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel.
###end article-title 183
###begin article-title 184
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
###end article-title 184
###begin article-title 185
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
###end article-title 185
###begin p 186
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: Under a licensing agreement between OncoMethylome Sciences, SA and the Johns Hopkins University, Dr. Sidransky is entitled to a share of royalty received by the University on sales of products described in this article. Dr. Sidransky owns OncoMethylome Sciences, SA stock, which is subject to certain restrictions under University policy. Dr. Sidransky is a paid consultant to OncoMethylome Sciences, SA and is a paid member of the company's Scientific Advisory Board. The term of this arrangement is being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
###end p 186
###begin p 187
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by National Cancer Institute (U01-CA84986) and Oncomethylome Sciences, SA, and Dutch Cancer Society (project number RUG 2004-3161). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 187

